Royal Bank of Canada Trims Theratechnologies (TSE:TH) Target Price to C$6.00

Theratechnologies (TSE:TH) had its price objective lowered by Royal Bank of Canada from C$7.00 to C$6.00 in a research report released on Wednesday, BayStreet.CA reports. The brokerage currently has a sector perform rating on the stock.

Other equities analysts have also recently issued reports about the stock. National Bank Financial decreased their price target on shares of Theratechnologies from C$11.25 to C$8.25 and set a sector perform rating for the company in a research report on Friday, July 12th. Mackie decreased their price target on shares of Theratechnologies from C$8.15 to C$7.00 and set a hold rating for the company in a research report on Friday, July 12th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of Hold and an average target price of C$8.75.

Shares of TSE:TH opened at C$4.90 on Wednesday. The company has a market cap of $387.84 million and a price-to-earnings ratio of -55.06. The company has a debt-to-equity ratio of 167.71, a current ratio of 2.51 and a quick ratio of 1.94. The firm has a 50 day simple moving average of C$5.35 and a 200 day simple moving average of C$6.27. Theratechnologies has a one year low of C$4.71 and a one year high of C$9.74.

Theratechnologies (TSE:TH) last issued its quarterly earnings data on Thursday, July 11th. The company reported C($0.06) EPS for the quarter. The company had revenue of C$20.92 million for the quarter, compared to analyst estimates of C$26.00 million. As a group, analysts expect that Theratechnologies will post 0.07 EPS for the current year.

Theratechnologies Company Profile

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.

Read More: Quiet Period Expirations

Analyst Recommendations for Theratechnologies (TSE:TH)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit